Abstract
The objective of this study were to assess the impact of a quality assurance effort on the door-to-needle time and the choice of thrombolytic agent for the management of acute myocardial infarction in the emergency department. The study design involved a prospective collection of data on a series of consecutive patients who received a thrombolytic agent for a presumed acute myocardial infarction. The study was carried out in the emergency department of a major university urban tertiary care center. A total of 349 patients were studied from September 1989 to March 1994. The quality assurance program began in 1989 and included chart review of all patients receiving thrombolytic therapy, with special attention to all patients with door-to-needle times >60 minutes to identify causes for delay. Feedback was directed to pharmacy, nursing, and physician staff. Biannual reports were distributed throughout the hospital and the emergency department. Nursing-specific feedback led to the development of protocols for all aspects of the delivery of thrombolytic agents. The choice of thrombolytic agent was not dictated by the protocol, but the physician staff was continuously updated on the results of the latest clinical trials comparing one thrombolytic agent with another. The mean age was 58 years for men and 67 years for women in this cohort consisting of 78% men and 22% women. Thirty-seven percent of the myocardial infarctions were in an anterior location and 56% were in an inferior location. The median duration of chest pain before presentation to the emergency department was 120 minutes. Hospital mortality was 3%. Median door-to-needle time fell from 46 (1989–1991) to 36 (1992–1994) minutes, P < 0.01. The percentage of patients with a door-to-needle time >60 minutes decreased from 35% (1989–1991) to 16% (1992–1994) minutes, P < 0.0001. Corresponding with the ISIS-3 report, there was a significant increase in the proportion of patients receiving streptokinase over the first 3 years of the study (P < 0.0001), which changed to a trend toward increased utilization of tissue plasminogen activator with the GUSTO report in the final 6 months of the study. In conclusion, a quality assurance program led to a significant reduction in the door-to-needle time, and recent megatrials were found to influence the choice of thrombolytic agent used.
Similar content being viewed by others
References
Gruppo Italiano per lo Studio della Streptochinase nell'Infarcto miocardio (GISSI). The GISSI Study Group. Effectiveness of IV thrombolytic therapy in acute myocardial infarction. Lancet 1986;1:397–401.
The ISAM Study Group. A prospective trial of intravenous streptokinase in acute myocardial infarction (ISAM): Mortality, morbidity, and infarct size at 21 days. N Engl J Med 1986;314:1465–1471.
ISIS-2 (Second International Study of Infarct Survival Collaborative Group). Randomized trial of intravenous streptokinase, oral aspirin, both or neither among 17187 cases of suspected myocardial infarction: ISIS-2. Lancet 1988;2:349–360.
Sharkey SW, Brunette DD, Ruiz E, et al. An analysis of time delays preceding thrombolysis for acute myocardial infarction. JAMA 1989;262:3171–3174.
Hartmann J, Mc Keever L, Bufalino V, et al. A system approach to intravenous thrombolytisis in acute myocardial infarction in community hospitals: The influence of paramedics. Clin Cardiol 1988;11:812–816.
Passamani E, Hodges M, Herman M, et al. The thrombolysis in myocardial infarction (TIMI) phase II pilot study: Tissue plasminogen activator followed by percutaneous transluminal coronary angioplasty. J Am Coll Cardiol 1987; 10 (Suppl. B):51B-64B.
Alderman EL, Jutzy KR, Berte LE, et al. Randomized comparison of intravenous versus intracoronary streptokinase for myocardial infarction. Am J Cardiol 1984;54:14–19.
Maynard C, Althouse R, Olsurfka M, Ritchie JL, Davis KB, Kennedy JW. Early versus late hospital arrival for acute myocardial infarction in the Western Washington thrombolytic therapy trials. Am J Cardiol 1989;63:1296–1300.
Weaver WD, Martin J, Litwin P, et al. Myocardial infarction triage and intravenous project-Phase I: Patient characteristics and feasibility of prehospital initiation of thrombolytic therapy. J Am Coll Cardiol 1990;15:925–931.
Keriakes DE, Weaver WD, Anderson JL, et al. Time delays in the diagnosis and treatment of acute myocardial infarction: A tale of eight cities. Report from the Pre-hospital Study Group and the Cincinnati Heart Project. Am Heart J 1990;120:773–779.
Gonzalez E R, Jones LA, Ornato JP. Hospital delays and problems with thrombolytic administration in patients receiving thrombolytic therapy: A multicenter prospective assessment. Ann Emerg Med 1992;21:1215–1221.
The BMDP statistical software package, release 7.0 (VAX/VMS), 1993.
Maynard CH, Weaver WD, Lambrew C, Bowlby LJ, Rogers WJ, Rubison RM. Administration of thrombolytic therapy with recombinant tissue plasminogen activator (data from the National Registry of Myocardial Infarction). Am J Cardiol 1995;76:548–552.
National Heart Attack Alert Program Coordinating Committee, 60 Minutes to Treatment Working Group. Emergency department: Rapid identification and treatment of patients with acute myocardial infarction. Ann Emerg Med 1994;23:311–329.
American Heart Association/Emergency Cardiac Care Committee and Subcommittees. Guidelines for cardiopulmonary resuscitation and emergency cardiac care, III. Adult advanced cardiac life support. JAMA 1992;268: 2199–2241.
Cummings P. Improving the time to thrombolytic therapy for myocardial infarction by using a quality assurance audit. Ann Emerg Med 1992;21:1107–1110.
Benson NH, Maningas PA, Krohmer JR. Guidelines for the prehospital use of thrombolytic agents. Ann Emerg Med 1994;23:1047–1048.
Rogers WJ, Bowlby LJ, Chandra NC, et al. Treatment of myocardial infarction in the United States (1990 to 1993): Observations from the National Registry of Myocardial Infarction. Circulation 1994;90:2103–2214.
Porter G, Doughty R, Gamble G, Sharpe N. Thrombolysis in acute myocardial infarction: Reducing inhospital treatment delay. N Z Med J 1995;108:253–254.
Cannon CP, Antman EM, Walls R, Braunwald, E. Time as an adunctive agent to thrombolytic therapy. Thrombos Thrombolys 1994;1:27–34.
Currie P, Gray SM, Shaw TRD, Starkey IR. Success of audit in reducing the time taken to administer thrombolysis and aspirin in patients with acute myocardial infarction. Scott Med J 1994;39:120–122.
Anderson W, Jackson RE, Wilson AG. Using quality improvement to decrease thrombolytic administration time. Ann Emerg Med 1994;23:633.
Krall SP, Reese CL. Effect of continuous quality improvement methods on reducing triage to thrombolytic interval for acute myocardial infarction. Acad Emergency Med 1995; 2:603–609.
Shah N, Edep M, Massie BM. Differences between cardiologists and heart failure specialists in the management of congestive heart failure. Circulation 1995 (Suppl. I);92: I666.
Cheseboro JH, Knatterud G, Roberts R, et al. Thrombolysis in Myocardial Infarctions (TIMI) trial, Phase I: A comparison between IV tissue plasminogen activator and IV streptokinase. Clinical findings through hospital discharge. Circulation 1987;76:142–154.
Gruppo Italiano per lo Studio della Soprravvivenza nell'Infarto Miocardico, GISSI-2: A factorial randomized trial of alteplase versus streptokinase and heparin versus no heparin among 12,490 patients with acute myocardial infarction. Lancet 1990;336:65–71.
ISIS-3 (Third International Study of Infarct-Survival) Collaborative Group. A randomized comparison of streptokinase vs. tissue plasminogen activator vs. anistreplase and of aspirin plus heparin vs.. aspirin alone among 41,299 cases of suspected acute myocardial infarction. Lancet 1992; 339:753–70.
The GUSTO Investigators. An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction. N Engl J Med 1993;329:673–682.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Guidry, U.A., Paul, S.D., Vega, J. et al. Impact of a Simple Inexpensive Quality Assurance Effort on Physician's Choice of Thrombolytic Agents and Door-to-Needle Time: Implication for Costs of Management. J Thromb Thrombolysis 5, 151–157 (1998). https://doi.org/10.1023/A:1008834230015
Issue Date:
DOI: https://doi.org/10.1023/A:1008834230015